Back to Top

Clinical Cancer Research (CCR)

Publisher :

American Association for Cancer Research (AACR)

Scopus Profile
Peer reviewed only
Scopus Profile
Open Access
  • pharmacology
  • animal studies
  • Cancer
  • +7

e-ISSN :

1557-3265

Issue Frequency :

Bi-Weekly

Impact Factor :

10.2

p-ISSN :

1078-0432

Est. Year :

1995

Mobile :

12154409300

DOI :

YES

Country :

United States

Language :

English

APC :

YES

Impact Factor Assignee :

Google Scholar

Email :

ccr@aacr.org

Journal Descriptions

Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, molecular alterations and biomarkers that predict response or resistance to treatment. The Journal will consider laboratory and animal studies of new drugs and molecularly-targeted agents that are approved for clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease. Specific areas of interest include clinical research in targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; novel applications of bioinformatics and biostatistics; immunotherapy and clinical immunology; antibody-based therapy; cellular and gene therapy; radiobiology and radiation oncology; large-scale molecular characterization of human tumors; innovative imaging and other novel methods with applicability to clinical investigation; clinical genetics; detection of minimal residual disease; and clinical artificial intelligence.


Clinical Cancer Research (CCR) is :

International, Peer-Reviewed, Open Access, Refereed, pharmacology, animal studies, Cancer, drug sensitivity, Clinical Oncology, Translational Medicine, Molecular Biology, Cancer Biology, Pharmacology, Biomarker Research , Online or Print, Bi-Weekly Journal

UGC Approved, ISSN Approved: P-ISSN - 1078-0432, E-ISSN - 1557-3265, Established in - 1995, Impact Factor - 10.2

Provide Crossref DOI

Indexed in Scopus, WoS, PubMed

Not indexed in DOAJ, UGC CARE

Publications of CCR

  • dott image January, 2020

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Purpose: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with...

Establish Your Own Journal Without the Expense!

OJSCloud offers a complete, free setup to get you publishing.

Start Your Free Journal!
free profile